Sertraline HCl sales will expand through 2036, with powder at 62.0% within the form segment and ≥99.5% at 57.0% of the purity grade category in 2026. The market was valued at USD 197.3 million in 2025 and is forecast to record a 2.4% CAGR between 2026 and 2036.